Ventyx Biosciences (VTYX) to Release Quarterly Earnings on Thursday

Ventyx Biosciences (NASDAQ:VTYX) is expected to issue its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect the company to announce earnings of ($0.44) per share for the quarter. Parties can find conference call details on the company’s upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Thursday, November 13, 2025 at 4:00 PM ET.

Ventyx Biosciences (NASDAQ:VTYX) last released its quarterly earnings data on Thursday, August 7th. The company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.07. On average, analysts expect Ventyx Biosciences to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Ventyx Biosciences Stock Down 1.7%

VTYX opened at $8.09 on Wednesday. The firm has a 50-day simple moving average of $3.81 and a two-hundred day simple moving average of $2.76. Ventyx Biosciences has a 52 week low of $0.78 and a 52 week high of $9.50. The company has a market capitalization of $576.90 million, a PE ratio of -4.82 and a beta of 1.23.

Analyst Upgrades and Downgrades

VTYX has been the subject of several research reports. Wall Street Zen raised shares of Ventyx Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, August 9th. Oppenheimer increased their price target on shares of Ventyx Biosciences from $9.00 to $14.00 and gave the company an “outperform” rating in a report on Monday, October 27th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Ventyx Biosciences in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Ventyx Biosciences currently has a consensus rating of “Hold” and a consensus target price of $10.00.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in VTYX. Hudson Bay Capital Management LP bought a new position in shares of Ventyx Biosciences in the 2nd quarter valued at about $34,000. Engineers Gate Manager LP bought a new stake in Ventyx Biosciences in the second quarter worth about $42,000. Jump Financial LLC bought a new stake in Ventyx Biosciences in the second quarter worth about $53,000. Jane Street Group LLC bought a new stake in Ventyx Biosciences in the first quarter worth about $56,000. Finally, Ameriprise Financial Inc. bought a new stake in Ventyx Biosciences in the second quarter worth about $60,000. Institutional investors own 97.88% of the company’s stock.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.